Gurkan Levent, Oommen Matthew, Hellstrom Wayne J G
Department of Urology, Tulane University Health Sciences Center, New Orleans, LA 70112, USA.
Asian J Androl. 2008 Jan;10(1):102-9. doi: 10.1111/j.1745-7262.2008.00369.x.
Premature ejaculation (PE) is recognized to be the most common male sexual disorder. PE provides difficulties for professionals who treat this condition because there is neither a universally accepted definition nor a medication approved by the Food and Drug Administration (FDA). Despite these shortcomings, physicians continue to diagnose their patients with PE according to major guidelines and treat them with either behavioral therapies or off-label medications. This review focuses on current and emerging treatment options and medications for PE. Advantages and limitations of each treatment option are discussed in the light of current published peer-reviewed literature.
早泄(PE)被认为是最常见的男性性功能障碍。早泄给治疗这种疾病的专业人员带来了困难,因为既没有一个被普遍接受的定义,也没有美国食品药品监督管理局(FDA)批准的药物。尽管存在这些缺点,医生们仍继续根据主要指南对他们的早泄患者进行诊断,并用行为疗法或非标签药物对他们进行治疗。本综述重点关注早泄的当前和新兴治疗选择及药物。根据当前已发表的同行评审文献,讨论了每种治疗选择的优缺点。